NCT05999682 is a Phase 1, PHASE2 clinical trial of apigenin in Sepsis, sponsored by Zhujiang Hospital.

Who is sponsoring NCT05999682?

NCT05999682 is sponsored by Zhujiang Hospital.

What drugs are being tested in NCT05999682?

Interventions in NCT05999682: apigenin, sterilized water.

What condition does NCT05999682 study?

NCT05999682 studies Sepsis, Septic Shock.

Is NCT05999682 still recruiting?

NCT05999682 is currently completed. Last updated 13 March 2024.

Last reviewed 2024-03-13 · How we verify

NCT05999682

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis

Completed Phase 1, PHASE2 Last updated 13 March 2024

What this trial tests

Phase 1, PHASE2 trial testing apigenin in Sepsis in 20 participants. Completed in 5 January 2024.

Timeline

1 September 2023

Primary endpoint
5 January 2024

5 January 2024

Quick facts

Lead sponsor	Zhujiang Hospital
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	1 September 2023
Primary completion	5 January 2024
Estimated completion	5 January 2024
Sites	1 location across China

Drugs / interventions tested

apigenin
sterilized water — full drug profile →

Conditions studied

Sepsis — all drugs for Sepsis →
Septic Shock — all drugs for Septic Shock →

Sponsor

Zhujiang Hospital

Who can join

65 and older, any sex, with Sepsis or Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this single-center, randomized, single-blind, placebo-controlled pilot clinical trial. The effect of apigenin on the improvement of organ function will be investigated in elderly patients with sepsis. Researchers will screen patients admitted to the Department of Critical Care Medicine at Zhujiang Hospital to identify patients with sepsis based on including and excluding criteria and obtain informed consent and randomize them into groups. The treatment group will be given apigenin tablets 50mg ground with 5ml of sterilized water for intra-gastric tube injection; the control group will be given an equal volume of sterilized water for intra-gastric tube injection. The changes in SOFA score and other clinically meaningful outcomes in 4 days will be collected.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Connecting epigenetics and inflammation in vascular senescence: state of the art, biomarkers and senotherapeutics.
Fraile-Martinez O, De Leon-Oliva D, Boaru DL, De Castro-Martinez P, et al · · 2024 · cited 8× · PMID 38469117 · DOI 10.3389/fgene.2024.1345459
Fibroblast PI3K/AKT signaling and extracellular matrix homeostasis: mechanisms, targets, and delivery challenges.
Fang C, Zeng Z, Ni B, Wen X, et al · · 2025 · PMID 41509070 · DOI 10.3389/fcell.2025.1681875
The Protective Activity of Apigenin Against Bone and Cartilage Diseases.
Chen J, Liao X, Wu L. · · 2025 · PMID 40827276 · DOI 10.2147/cia.s529148

Verify or expand the search:

Other recruiting trials for Sepsis

Currently open trials in the same condition.

NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting

Other Zhujiang Hospital trials

Trials by the same sponsor.

NCT07335094 — A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lym · EARLY_PHASE1 · not yet recruiting
NCT07469072 — Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in t · Phase 2 · recruiting
NCT07455149 — An Observational Clinical Study on the Association of Intestinal Ruminococcus Gnavus and Its Derived Biogenic Amines Wit · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07454421 — Racecadotril for Organ Injury in Sepsis Patients · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05999682 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhujiang Hospital
Last refreshed: 13 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05999682.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing